Table 1. Baseline and follow-up characteristics of men and women initiated on ART.
Variable | Men (N = 1457) |
Women (N = 2586) |
p-value |
---|---|---|---|
Characteristics at ART initiation | |||
Overall age (years), median(IQR) | 35 (30–41) | 32 (28–38) | <0.001 |
Age group: n (%) | |||
<24 | 45 (3.1) | 232 (9.0) | <0.001 |
24–34 | 655 (45.0) | 1350 (52.3) | |
35+ | 757 (52.0) | 1001 (38.8) | |
BMI(kg/m2), median(IQR) | 21 (19.0–3.2) | 24.2 (21.1–28.1) | <0.001 |
CD4+ cell count (cells/mm3), median(IQR)a | 113 (47–177) | 131 (68–189) | <0.001 |
CD4+ cell count, cells/mm3: n (%) | |||
<50 | 344 (25.9) | 423 (18.3) | <0.001 |
50–200 | 783 (58.9) | 1428 (61.6) | |
>200 | 203 (15∙3) | 466 (20.1) | |
Log VL, mean(SD)b | 5∙0 (0.9) | 4.9 (0.9) | <0.001 |
Rural site, n (%) | 692 (47.5) | 1536 (59.4) | <0.001 |
Urban site, n (%) | 765 (52.5) | 1050 (40.6) | |
WHO stage 1–3, n (%)c | 1244 (85.7) | 2315 (90.3) | <0.001 |
WHO stage 4, n (%)c | 208 (14.3) | 250 (9.7) | |
Previous history of TB, n (%)d | 483 (34.4) | 661 (26.3) | <0.001 |
Prevalence of TB, n (%) | 467 (32.1) | 505 (19.5) | <0.001 |
Follow-up | |||
Number initiated on second line ART, n (%) | 104 (7.1) | 245 (9.5) | 0.012 |
Lost to follow-up | 161 (11.1) | 239 (9.2) | 0.070 |
a396 patents had missing baseline CD4+ count,
b496 missing VL,
c26 missing WHO stage,
d121 missing previous history TB